SCHEMBL10272785

SCHEMBL10272785

CCc1cc(N2CCOCC2)nc(-c2ccccc2)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.75
LMNA P02545 1/20 0.75
HTT P42858 2/20 0.74
MTOR P42345 3/20 0.72
MAPT P10636 4/20 0.68
NPSR1 Q6W5P4 2/20 0.68
TSHR P16473 1/20 0.68
MAPK1 P28482 1/20 0.68
HSD17B10 Q99714 1/20 0.68
MEN1 O00255 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.59
CYP1A2 P05177 4/20 0.57
CYP2C9 P11712 4/20 0.57
CYP2C19 P33261 4/20 0.57
ALDH1A1 P00352 3/20 0.57
CYP3A4 P08684 2/20 0.57
ADRB2 P07550 1/20 0.57
ATR Q13535 1/20 0.56
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003396 0.86 HTT (0.74) KMT2ALMNAHTTMTORMAPT
SCHEMBL1271201 0.86 KMT2A (1.00) KMT2ALMNAHTTMTORMAPT
SCHEMBL1270069 0.86 MAPT (0.77) KMT2ALMNAHTTMTORMAPT
SCHEMBL10224015 0.86 KMT2A (0.70) KMT2ALMNAHTTMTORMAPT
SCHEMBL1271558 0.84 KMT2A (0.67) KMT2ALMNAHTTMTORMAPT
SCHEMBL1271420 0.84 MTOR (1.00) KMT2ALMNAHTTMTORMAPT
SCHEMBL1272267 0.82 KMT2A (0.76) KMT2ALMNAHTTMTORMAPT
SCHEMBL3452088 0.81 MAPT (1.00) KMT2ALMNAHTTMTORMAPT
SCHEMBL27732853 0.81 HTT (0.65) KMT2ALMNAHTTMTORMAPT
SCHEMBL27732850 0.81 HTT (0.65) KMT2ALMNAHTTMTORMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT KMT2A 4058/4885LMNA 824/4885HTT 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.